IL2 and melanoma: A clinical trial (NCT01740557) was initiated to evaluate the efficacy of T cells transduced with CXCR2 and with nerve growth factor receptor (NGFR), associated with Recombinant Human IL-2 (Aldesleukin) infusion in melanoma (Table 10).